Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MONOKET vs MINITRAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing c GMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
Acute angina pectoris,Prophylaxis of angina pectoris (prior to activities that may provoke an attack),Chronic angina (off-label: long-term prophylaxis),Heart failure associated with acute myocardial infarction (off-label)
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Rapidly metabolized in the liver by glutathione-organic nitrate reductase, with minor contributions from vascular wall and RBC metabolism. Metabolites include 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal.
Isosorbide mononitrate is less than 5% bound to plasma proteins.
Approximately 60% bound to plasma proteins (albumin).
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Vd is about 3 L/kg, indicating extensive tissue distribution.
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
Transdermal: approximately 70-80% of the dose reaches systemic circulation.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
No specific dose adjustment required for renal impairment. However, patients with severe renal insufficiency (Cr Cl <30 m L/min) may have increased risk of adverse effects; monitor closely.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
No specific dose adjustment recommended for Child-Pugh A or B. For Child-Pugh C (severe hepatic impairment), consider reducing dose due to reduced metabolism and increased risk of hypotension; use with caution.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Safety and effectiveness in pediatric patients have not been established. Use only under expert guidance. Typical initial dose: 0.1-0.2 mg/hour transdermally, titrated cautiously based on clinical response and tolerance.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
Elderly patients may be more sensitive to the hypotensive effects. Start at the lower end of dosing range (0.2 mg/hour) and titrate slowly. Monitor blood pressure and heart rate regularly.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Do not use MINITRAN in patients taking phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) as this can cause severe hypotension. Additionally, MINITRAN should not be used in patients with early myocardial infarction or severe anemia.
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypotension; paradoxical bradycardia; tolerance (need for nitrate-free interval); exacerbation of angina with abrupt discontinuation; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
Concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe anemia; increased intracranial pressure (e.g., head trauma, cerebral hemorrhage); acute circulatory failure; hypersensitivity to nitrates.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
Concurrent use of alcohol can cause vasodilation and hypotension. Limit or avoid alcohol. No specific food restrictions.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trimesters: risk of fetal bradycardia, hypotension, and decreased placental perfusion.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
Likely excreted in breast milk. M/P ratio not established. Use with caution; monitor infant for hypotension.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
No specific dose adjustments recommended, but use lowest effective dose due to potential for hypotension and decreased placental perfusion.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
MINITRAN (nitroglycerin transdermal) is used for angina prophylaxis, not acute attacks. Apply to hairless area, rotate sites, and remove for 12-14 hours daily to prevent tolerance. If headache occurs, reduce dose or use acetaminophen. Do not discontinue abruptly to avoid rebound ischemia.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
Apply patch to clean, dry, hairless skin on chest, arm, or back; rotate sites daily.,Remove patch after 12-14 hours to prevent tolerance; apply new patch at same time next morning.,Do not use for acute angina; use sublingual nitroglycerin instead.,Avoid alcohol and erectile dysfunction drugs like sildenafil; can cause severe hypotension.,Headache may occur; use acetaminophen or reduce dose; do not stop abruptly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MONOKET vs MINITRAN, answered by our medical review team.
MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. MINITRAN is a Nitrate Vasodilator that works by Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing c GMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MONOKET and MINITRAN depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. The standard adult dose of MINITRAN is: Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MONOKET and MINITRAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. MINITRAN is classified as Category C. Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trim. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.